Last updated: February 13, 2026
What is the current clinical trial status for MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE?
There are no publicly listed ongoing or upcoming clinical trials for MOEXIPRIL Hydrochloride combined with Hydrochlorothiazide in major registries such as ClinicalTrials.gov, the EU Clinical Trials Register, or WHO International Clinical Trials Registry Platform. Previous trials, conducted primarily in the 1990s, focused on the antihypertensive efficacy and safety profile of the combination.
Historical Data:
- Initial studies demonstrated reductions in systolic and diastolic blood pressure with the combination.
- Trials involved doses ranging from 7.5/25 mg to 30/50 mg.
- The drug was approved in select countries in the late 1990s but did not attain widespread adoption.
Implication: No current clinical activity suggests the drug is not under active development or testing phases.
How does the market landscape for combination antihypertensive therapies look?
Market Size and Growth:
- The global antihypertensive drugs market reached approximately USD 14 billion in 2022.
- A compound annual growth rate (CAGR) of 3-4% for the next five years is projected, driven by increasing hypertension prevalence, particularly in aging populations and emerging markets (Reference [1]).
Key Players and Formulations:
- The market is dominated by angiotensin receptor blockers, ACE inhibitors, calcium channel blockers, and diuretics.
- Fixed-dose combinations (FDCs), especially those combining an ACE inhibitor or ARB with a diuretic, capture a significant share due to improved compliance and convenience.
| Competitive Landscape: |
Drug Name |
Active Ingredients |
Market Status |
Approximate Market Share (2022) |
| ACE inhibitor + HCTZ |
Lisinopril + HCTZ, Enalapril + HCTZ |
Well-established |
35% |
| ARB + HCTZ |
Losartan + HCTZ, Olmesartan + HCTZ |
Growing |
25% |
| Other combinations |
Various |
Niche |
15% |
Regulatory Environment:
- The U.S. FDA approves multiple fixed-dose combinations without requiring phase 3 studies if bioequivalence and safety are established.
- Patent expiry of certain formulations leads to generic competition.
What are the key factors influencing projection and future outlook?
Clinical Utility:
- MOEXIPRIL is an ACE inhibitor used to reduce blood pressure.
- Hydrochlorothiazide (HCTZ) is a thiazide diuretic.
- The combination aligns with standard hypertension management protocols but faces stiff competition from existing, approved combinations with proven market acceptance.
Regulatory and Patent Status:
- Patent protection for MOEXIPRIL expired around the early 2010s.
- Generic versions of MOEXIPRIL are available, reducing barriers to market entry but also diminishing potential margins for new entrants.
Market Adoption Barriers:
- No recent clinical trials to establish comparative efficacy or improved safety profile.
- Existing drugs with established biosimilarity and proven outcomes reduce the incentive for reintroduction unless new data emerges.
Future Growth Potential:
- Indicated primarily for patients requiring combination therapy.
- Without new clinical data, market growth prospects for MOEXIPRIL HCTZ are limited.
- Potential niche markets exist in regions with less generic drug penetration or specific formulary preferences.
What strategic considerations should stakeholders evaluate?
- Development investments: High costs without current clinical activity; unlikely to benefit from re-entry unless novel data surfaces.
- Market opportunities: Focus on differentiated formulations, such as sustained-release or fixed-dose combinations with novel agents.
- Regulatory pathway: Generic status limits patent-based exclusivity, requiring differentiation via clinical data or formulation innovatio.
Summary of Key Market and Clinical Data
| Aspect |
Data Point |
| Market size |
USD 14 billion (2022) |
| Growth rate |
3-4% CAGR (next 5 years) |
| Market share of combined therapies |
75-85% (depending on region) |
| Clinical trial activity |
None recent or ongoing |
| Patent status |
Expired in early 2010s |
| Competitive products |
Lisinopril+HCTZ, Losartan+HCTZ |
Key Takeaways
- No active clinical trials for MOEXIPRIL Hydrochloride with Hydrochlorothiazide.
- The drug faces significant market competition from well-established fixed-dose combinations.
- Market growth hinges on differentiation via clinical benefits, formulation innovation, or targeted regional use.
- Patent expiry and availability of generics diminish the commercial viability unless new trial data justifies renewed interest.
- Stakeholders should compare the cost-effectiveness of developing new clinical data against marketing existing formulations.
FAQs
1. Why are there no current clinical trials for MOEXIPRIL HCTZ?
Most clinical development likely ceased after patent expiration and commercial decline, with no recent data indicating ongoing testing due to stiff competition and market saturation.
2. Can MOEXIPRIL-based formulations still be marketed?
Yes, generics are available; however, launching a new formulation without clinical benefits offers limited commercial value.
3. What advantages could a new trial provide?
Demonstrating superior efficacy, reduced side effects, or improved compliance could differentiate MOEXIPRIL HCTZ in a crowded market.
4. How does the patent landscape affect market prospects?
Patent expiry opens access for generics but also eliminates exclusivity, making market share dependent on price and clinical differentiation.
5. What regions offer potential growth?
Emerging markets with lower penetration of established drugs may present niche opportunities, especially if local regulatory pathways favor less well-known formulations.
References
[1] GlobalData, "Antihypertensive Drugs Market Report," 2022.
